Activation of refill synthesis is dependent on intact nitric oxide production. The present study investigated whether or not nitric oxide (NO) synthesis mediates mechanisms regulating activation of renin formation. Studies were performed on afferent arterioles freshly isolated from the rat kidney. We have shown previously that this preparation is a useful model to study regulation of renin synthesis and secretion. The expression of renin mRNA was assessed by ribonuclease protection assay, and total renin content and renin secretion by radioimmunoassay. In afferent arterioles isolated from rats treated with the angiotensin-converting enzyme inhibitor ramipril, renin mRNA levels, total renin content and renin secretion were increased threefold compared to untreated controls.
The renin-angiotensin system (RAS) plays a major role in the regulation of renal and cardiovascular functions. It is well known that renin release is influenced by changes in arterial pressure, sodium intake, activity of sympathetic nerves, and plasma concentration of several hormones [1] . However, the cellular mechanisms controlling renin secretion are not yet fully understood. In particular, conflicting data are reported about nitric oxide (NO) influences on renin release and/or synthesis and the mechanisms involved. Early reports were in favor of an inhibitory role of NO on renin secretion through guanylate cyclase activation. Thus, NO donors inhibited renin release in rat cortical slices, whereas inhibition of NO synthesis increased plasma renin activity in conscious dogs and anesthetized rats [2] [3] [4] . However, other recent investigations revealed a more complex interaction of NO with renin secretion. For example, in cultured mouse juxtaglomerular cells, NO donors had a dual effect on renin secretion: an early inhibitory effect, probably due to stimulation of guanylate cyclase, and a late stimulatory effect that was mediated by an as yet unidentified pathway [5] . In addition, inhibition of NO synthesis reduced plasma renin levels and renin release in high RAS activity models (the anesthetized or furosemide-treated rat, and the isolated perfused rat kidney) [6] [7] [8] . It is interesting to note that the most widely used experimental approach in the NO-RAS interaction studies was to inhibit endogenous NO synthesis. It is possible that some of the effects of NO blockade on renin release were due to an altered balance between NO and vasoconstrictors such as angiotensin II or endothelin (well-known activators of Ca2 influx and inhibitors of renin formation [1] ). No data have been reported to date evaluating a possible involvement of these renal vasoeonstrictors on the regulation of renin secretion and synthesis when NO production is inhibited.
Recently, we developed a preparation of afferent arterioles freshly isolated from the rat kidney to study the properties of angiotensin II receptors [9] . In subsequent studies we refined this vascular preparation to study the autocrine and paracrine regulation of the RAS [10] . In addition, we have observed that inhibition of NO blunted the in vitro, forskolin-induced increase of renin secretion [11] .
The purpose of the present studies was to evaluate whether or not and by which mechanism(s) NO affects the activity of the RAS when stimulated by various mechanisms. For this reason, renin synthesis was stimulated by converting enzyme inhibition or by a diuretic acting on the macula densa cells, with or without inhibition of endogenous NO synthesis. Measurements of renin secretion, tissue content and mRNA levels were performed in the above-mentioned model of isolated afferent arterioles. Our find-
Methods
Animal treatment Male Sprague-Dawley rats were maintained on a normal salt diet and weighed 150 to 200 g at the time of the experiments.
Animals had free access to chow and tap water. To activate renin synthesis, rats were treated with ramipril (10 mg/kg/day), an angiotensin converting enzyme inhibitor or furosemide (20 mg/ kg/day), a diuretic agent that inhibits Na4 /K/2Cl cotransport in macula densa cells. In some of the ramipril-treated rats, N-nitro-L-arginine methyl ester (L-NAME), a NO synthase inhibitor, was coadministered at a dose of 10 mg/kg/day. In previous studies we found that this dose is the minimum required for a sufficient blockade of endogenous NO synthesis in the rat without altering the mean arterial pressure till. In a separate group of ramipril-or ramipril + L-NAME-treated rats, bosentan 30 mg/kg/day (an endothelin receptor antagonist) was administered. All in vivo treatments lasted five days. Previous studies revealed that this duration is enough to activate renin synthesis and release, and to block NO without affecting blood pressure [11] .
In some ramipril-or ramipril + L-NAME-treated rats, the L-type channel calcium blocker, nicardipine, or the mixed endothelin receptor (ETA and ETB) antagonist, bosentan [121, were administered into the kidneys at the concentration of 1 and 10 M, respectively, immediately before the kidneys were removed. All subsequent steps until the isolation of afferent arterioles were carried out in the presence of 1 /.LM nicardipine or 10 /.tM bosentan.
Six to 12 rats were used to isolate afferent arterioles for each experiment. Each series of experiments consisted of at least four independent experiments.
Measurement of blood pressure Systolic blood pressure was measured by the tail-cuff method (W+W electronic recorder 8005; Apelab, Bagneux, France). Measurements were done before, and five days after the first administration of drugs.
Isolation of afferent arterioles
The technique to isolate afferent arterioles from the rat kidney was the same as previously described [9-il] . Briefly, in rats anesthetized with pentobarbital, a midline abdominal incision was made, and the abdominal aorta was cannulated below the renal arteries. The aorta above the kidney was ligated, the left renal vein was cut, and kidneys were perfused with iced isotonic saline solution until all blood was removed. Thereafter the kidneys were perfused with a magnetized iron oxide suspension (1% Fe3O4 in isotonic saline). All subsequent steps of isolation were performed at 4°C. The kidneys were removed, decapsulated, and the cortex was dissected from the medulla. Cortical tissue was homogenized with a Polytron homogenizer, and the iron oxide-loaded tissues (renal vessels and glomeruli) were removed from the crude homogenate with the aid of a magnet. Affcrent arterioles were separated from larger vessels and glomeruli using repetitive passages through needles and sieves of decreasing diameter sizes (20 to 23 gauge and 150 to 90 j.tm, respectively). The microvessels were recovered from the top of the 125 m sieve. To determine if parts of afferent arterioles stayed attached to glomeruli during the separation process, glomeruli were collected in parallel using a 75 j.tm sieve and examined under light microscopy. Only a minor part of isolated glomeruli (< 3%) had an attached portion of an afferent arteriole. Vascular preparations containing > 90% of afferent arterioles were retained for subsequent experiments. Protein content was estimated according to Bradford's method [13] .
Renin release evaluation
Aliquots of microvessels (100 to 200 j.tg of protein) were incubated at 37°C in a final volume of 0.5 ml of RPMI medium. To determine the intracellular renin content, microvessels were treated with 0.1% Triton X100 for 30 minutes at room temperature. Total renin content was defined as the sum of released renin and intracellular renin content. Renin activity was measured by radioimmunoassay as the amount of angiotensin I (Ang I) produced by incubation of supernatants with an excess of rat renin substrate (plasma of binephrectomized rats). Renin activity was expressed in nanograms of Ang I generated per hour of incubation per milligram of protein of afferent arterioles. Measurements of renin secretion and synthesis were performed after 30 minutes, two hours and four hours incubation of afferent arterioles in RPMI, according to previously published data [11] . Three to six measurements were performed per condition/per experiment.
Measurement of preprorenin mRNA expression
The method to determine the mRNA of preprorenin from rat afferent arterioles was similar to that previously described [14] . Briefly, total RNA was extracted from the vessels according to the protocol of Chomczynski and Sacchi [15] . Renin mRNA was measured by ribonuclease protection assay. A preprorenin complementary RNA probe containing 296 bp of exons I and II (made from a pGEM-4 vector carrying a PstI-KpnI restriction fragment of a rat preprorenin eDNA) was generated by transcription with SP6 RNA polymerase. Transcripts were labeled with 32P-UTP (15 TBq/mmol, ICN). For each sample, increasing amounts of total RNA (from 10 to 30 jig) were hybridized with the renin probe. The amount of total renal RNA commonly used for renin RPA is 20 jig [7, 14, 161 . Since our studies were performed using afferent arterioles (a tissue of higher concentration in renin than whole kidney) and in conditions of activation of renin synthesis, we tested increasing amounts of total RNA to verify that saturation of the signal did not occur. Ribonuclease digestion was carried out with A and T RNase, and the protected mRNA fragments were purified by phenol-chloroform extraction, ethanol precipitation and electrophoresis in a 8% polyacrylamide gel. After autoradiography of the dried gels for 12 to 48 hours, bands representing protected renin mRNA fragments were quantified by densitometry (Adobe Photoshop System) and by measurement of radioactivity (32P, after excision of bands) on a liquid scintillation counter (1211 Rackbeta, LKB). In each hybridization, a renin mRNA standard was included consisting of RNA extracted from afferent arterioles of control Sprague-Dawley rats.
Statistical methods
Statistical analyses were performed using the Statview software package. Results with P < 0.05 were considered statistically significant. All values are means s.
Results
A primary goal was to investigate whether or not NO is involved in the physiological mechanisms producing activation of the RAS.
The design was to stimulate renin formation and evaluate responses to inhibition of NO synthesis. To this end, animals were treated with ramipril, an angiotensin-converting enzyme inhibitor and potent activator of renin synthesis and secretion, and L-NAME, a potent inhibitor of NO-synthase. Treatment of rats with these agents did not change body or kidney weights (data not shown). In rats treated with ramipril, systolic blood pressure did not change compared to control values (106 6 vs. 120 6 mm Hg, P > 0.2). When ramipril and L-NAME were administered simultaneously, systolic blood pressure increased slightly (135 8 vs. 120 6 mm Hg, P > 0.5), and increased significantly compared to ramipril-treated rats (135 8 vs. 106 6 mm Hg, P < 0.01).
Since differences in secretion, tissue content and mRNA of renin among animal groups were similar and were independent of the period of afferent arteriole incubation (30 mm, 2 or 4 hr), data are presented for the two-hour time period to avoid unnecessary repetition. Treatment of the animals with the angiotensin-converting enzyme inhibitor to block angiotensin II formation markedly activated renin synthesis. Renin secretion and tissue renin content in afferent arterioles isolated from ramipril-treated rats increased two-to threefold compared to controls ( Similar increases were observed in the renin mRNA levels extracted from the afferent arterioles of the ramipril-treated rats. The protected fragment of renin mRNA from the ramipril-treated group was threefold higher than control in all tested concentrations of total RNA (Fig. IB) . Inhibition of NO production by L-NAME completely blocked the ramipril-induced activation of renin formation since mRNA levels, tissue content and secretion of renin in the afferent arterioles obtained from the ramipril + L-NAME-treated animals were reduced to levels similar to controls ( Fig. 1 ).
To investigate if the inhibitory effect of L-NAME on renin synthesis is specific to angiotensin-converting enzyme inhibition, the RAS was activated with a different maneuver (furosemide administration) in a separate group of animals. Furosemide treatment did not affect systolic arterial pressure (124 6 vs. 1117 5 mm Hg). Renin release and tissue renin content were increased two-to threefold in arterioles of the furosemide-treated animals compared to control (renin release 18,345 2,056 vs. 5,658 502 ng/mg/hr, P < 0.01, and renin content 56,507 6, 250 vs. 24,125 2,435 ng/mg/hr, P < 0.01; Fig. 2) . Similarly, the expression of renin mRNA was increased two-to threefold by furosemide treatment (at 20 mg total RNA, 495 56 vs. 212 37 cpm, P < 0.01). As was the case with ramipril + L-NAME rats, administration of L-NAME to the furosemide-treated rats suppressed renin formation (renin release 7,150 717 ng/mg/hr; renin content 30,520 3,245 ng/mg/hr, Fig. 2 ; renin mRNA 235 31 cpm).
Since the major physiological inhibitory mechanism of renin activation is an increase in intracellular calcium concentration in the renin producing cells, we examined whether blockade of calcium entry in affcrent arterioles altered the effect of L-NAME on the activation of renin synthesis. In these studies, nicardipine, an L-type calcium channel blocker, was added to afferent arterioles isolated from ramipril + L-NAME-trcated rats. As shown in Figure 3A , nicardipine had no effect on renin release of ramipril-treated animals. In sharp contrast, nicardipine canceled the inhibitory effect of L-NAME and completely restored renin secretion to stimulated levels observed in ramipril-treated rats (8, 352 1,687 vs. 16,482 1,895 ng/mg/hr, P < 0.05 for ramipril + L-NAME-treated rats in absence and presence of nicardipine, respectively). However, nicardipine had no effect on tissue renin content (Fig. 3B ). Contrary to changes of renin secretion that are immediate, changes in renin synthesis are late phenomena. To examine if renin transcription was reactivated by nicardipinc, renin mRNA measurements were performed in afferent arterioles isolated from ramipril + L-NAME-treated rats in the presence or absence of nicardipine for four hours. As reported above, we confirmed that expression of renin mRNA in the ramipril + L-NAME group was threefold lower than in the ramipril group. 
30000
A Addition of nicardipine in these vessels for a period up to four hours did not significantly change renin mRNA expression (data not shown).
To gain insight into the mechanism(s) responsible for the increased calcium entry occurring during the inhibition of NO in affercnt arterioles, we investigated which agent increasing calcium influx in vascular smooth muscle cells could be involved in the inhibitory effect of L-NAME. Our results with ramipril excluded the possibility that this agent was angiotensin II, because during inhibition of converting enzyme the endogenous levels of angiotensin II are negligible. Another potential candidate was endotheliri, a potent vasoconstrictor and renin release inhibitor [17] .
To test this hypothesis, bosentan, an antagonist of endothelin receptors (ETA and ETB), was added to afferent arterioles isolated from ramipril + L-NAME-treated rats. As shown in Figure 4 , bosentan mimicked the effect of nicardipine since it canceled the inhibitory effect of L-NAME and completely restored renin secretion to stimulated levels observed in ramipriltreated rats (4,886 682 vs. 19,212 4,005 ng/mg/hr, P < 0.01 for ramipril + L-NAME-treated rats in absence and presence of bosentan, respectively, Fig. 4A ). In the absence of L-NAME, bosentan did not affect renin release of ramipril-treated rats (Fig.  4B) . As was the case with nicardipine, bosentan had no effect on tissue renin content (Fig. 4B) .
The above results suggest that endothelin-induced calcium influx could mediate the inhibitory effect of L-NAME on renin synthesis. To verify whether this mechanism occurs in the whole animal in vivo, rats were treated with ramipril and L-NAME and/or bosentan. In vivo administration of bosentan had no effect on systolic blood pressure (125 7 vs. 127 7 mm Hg, in agreement with the literature for this dose and period of treatment) [18, 191, or on renin release and synthesis (Fig. 5) . Similarly, hosentan did not change the systolic pressure of ramipril + L-NAME-treated rats (130 7 vs. 134 6 mm Hg). In contrast, in the vessels obtained from the ramipril + L-NAME + bosentantreated animals, renin release was increased twofold compared to afferent arterioles isolated from ramipril + L-NAME-treated rats (12,358 1,256 vs. 6,090 712 ng/mg/hr, P < 0.01, Fig. 5A) . Fig. 6 ). Note that treatment with bosentan did not completely re-establish renin formation (renin release 5 and 6 ). Thus, hosentan applied chronically, but not acutely (Fig. 4) , partially restored renin transcription and synthesis. As mentioned above, changes in renin synthesis are late phenomena, and the lack of stimulation of renin synthesis in presence of bosentan or nicardipine in vitro was probably due to time restraints. The present study provides new information about the mechanism(s) regulating the activation of the renin formation, Specifically, our results highlight the importance of production of endogenous NO as a mediator in this activation. Levels of mRNA, tissue content and secretion of renin were measured under conditions of activation of renin formation in the presence or absence of pharmacological blockade of NO synthesis. Renin synthesis was activated in vivo by two distinct mechanisms: angiotensin-converting enzyme inhibition (angiotensin II dependent) and salt transport inhibition (macula densa dependent). In both cases, inhibition of NO synthesis by L-NAME blunted the activation of renin synthesis. A novel finding was that the suppressor effect of L-NAME was offset by nicardipine, a calcium entry blocker, and by the endothelin receptor antagonist bosentan. Thus, this study presents new evidence concerning the Several experimental approaches have been used to investigate whether or not NO influences renin release and/or synthesis. Some investigators reported that inhibition of NO synthesis stimulated renin release in rat cortical slices, conscious dogs and anesthetized rats [2] [3] [4] . In contrast, other investigators found that NO stimulated renin release in juxtaglomerular cultured cells, isolated perfused kidney, anesthetized rats or conscious dogs [5] [6] [7] [8] 201 . It is possible that NO originating from different cellular sources may exert different effects on renin release. Consistent with this notion, the effect of NO appears to be stimulatory or inhibitory on renin secretion depending on the site of NO production and on the target cells (macula densa cells, vascular smooth muscle cells, NO applied on bath or lumen of isolated perfused juxtaglomerular apparatus) [21] [22] [23] .
Recently, we refined a preparation of freshly isolated afferent arterioles to study regulation of the RAS [9-111. In this model it is difficult to study the exact site of NO synthesis. However, this vascular preparation offers some specific advantages. A more representative population and a better homogeneization of afferent arterioles can be achieved, because tissue from 4 to 6 rats per condition/per experiment is pooled. The microvcssels are freshly isolated, thus excluding changes of cell phenotype. Finally, this model is responsive to functional changes of renin regulation resulting from an in vivo treatment, thus making feasible a comprehensive evaluation of mechanisms governing renin activation in vivo [11] .
The most intriguing observation of our recent studies was that NO inhibition impaired the mechanism(s) controlling in vitro stimulation of renin release [11] . The present studies extend this initial observation to a more physiologically relevant content and provide new insights into mechanisms involved in stimulation of renin synthesis. In vivo treatment of animals with an angiotensinconverting enzyme inhibitor strongly increased renin secretion, renin synthesis and renin mRNA levels, which is in agreement with previous studies on microdissected afferent arterioles and whole kidney homogenates [14, 24J. Inhibition of NO synthesis by L-NAME completely abolished the increase in renin rates of transcription, synthesis and secretion. A similar inhibitory effect of L-NAME on renin mRNA levels was previously observed in whole kidneys obtained from rats treated with the ACE inhibitor, perindopril [14] . Some of the suppression in renin activation may have resulted from the L-NAME-induced increase in arterial pressure. However, no correlation was observed between the expression of renin mRNA levels and mean systolic pressure in the L-NAME + ACE inhibitor-treated animals [14] . In conscious rats, the pressure-dependent mechanism of renin release was activated at values of arterial pressure < 95 mm Hg, whereas it had little or no effect when arterial pressure was > 95 mm Hg [25] . Total RNA, tg
In addition, treatment with L-NAME exhibited the same suppression of RAS actLvity in the furosemide-treated rats (Fig. 2) , where no changes in arterial pressure were observed. These data imply that the mechanism(s) by which L-NAME blocks renin stimulation is (are) independent of systemic hemodynamic changes. It is interesting to note that the inhibitory effect of L-NAME was noted whether or not the activation of renin synthesis was due to a reduction in endogenous angiotensin II levels (ramipril) or in macula densa-mediated ion transport (furosemide). Similarly, L-NAME inhibited the increase of renin mRNA expression in whole kidneys of rats treated with an angiotensin receptor antagonist (losartan) or low sodium intake [7] . These findings strongly suggest that NO inhibition interacts with renin activation at a major step, one that seems to be common to these different stimuli.
Since the major intracellular signal inhibitory to renin productin is an increase in cytosolic-free calcium concentration, we evaluated the possibility that NO inhibition suppressed stimulation of renin formation by increased calcium entry into the renin-producing cells. The fact that nicardipine completely abolished the L-NAME effect suggests that an increase in cytosolic calcium concentration in afferent arterioles is mainly mediated by calcium influx through voltage-sensitive L-type channels. The existence of L-type calcium channels has been questioned in cultured juxtaglomerular cells from mice [261. However, in the in situ perfused rat kidney, Navar et al have observed that activation of voltage-operated calcium channels is the major event leading to calcium entry in afferent arterioles [27] . More recently it was observed that L-type calcium channels mediate at least half of the angiotensin IT-induced constriction in freshly isolated afferent arterioles (preparation similar to ours) or in cultured vascular smooth muscle cells obtained from afferent arterioles [281. Acute application of nicardipine restored renin secretion, but not renin synthesis or mRNA expression. It is possible that the kinetics of renin secretion are much faster than those of renin synthesis, and the time of exposure of arterioles to nicardipine (4 hr) was not enough to elicit changes in mRNA levels. In support to this view, increased renin secretion in response to forskolin was detected almost immediately in cultured juxtaglomerular cells, whereas at least three hours were required to observe increased levels of mRNA [29] .
Little is known about NO-mediated inhibition of calcium entry in vascular smooth muscle or juxtaglomerular cells. It is reported that NO-synthase inhibitors induced accumulation of intracellular calcium in cultured vascular smooth muscle cells by reducing protein kinase G activity [30] . Alternatively, NO could regulate the function of ion channels directly without requiring cGMP. In this regard, NO is reported to activate calcium-dependent potassium channels in rabbit aorta irrespective of guanylate cyclase activation [31] . An attractive hypothesis is that NO interferes with the action of one or several agents, such as angiotensin II or endothelin, stimulating calcium entry into smooth muscle cells. Our data obtained with bosentan, an antagonist of endothelin receptor, are in agreement with this hypothesis. Acute treatment of afferent arterioles with bosentan mimicked the effect of nicardipine and restored renin secretion to activated levels (Fig. 4) . In favor to this notion, recent reports indicate that endothelin inhibited the cAMP-mediated activation of renin synthesis through a calcium channel-dependent mechanism in juxtaglomerular cells cultured in vitro [32, 33] . To verify whether the NO inhibition-endothelin mechanism occurs in vivo, we coadministered L-NAME and/or bosentan with ramipril. Chronic treatment with bosentan altered the effect of L-NAME and reactivated renin synthesis, confirming our hypothesis. The fact that renin production was partially restored could be due to dose restraints (we used the minimum required to avoid hemodynamic effects) or to another agent mediating calcium entry. If the latter was the case, this agent would not be angiotensin II since L-NAME inhibited activation of renin synthesis in ramipril-treated animals (where synthesis of angiotensin II is blocked). This is in agreement with the observation that the renal hemodynamic response to NO inhibition is not mediated by endogenous angiotensin II in conscious rats [341. In support of the NO-endothelin interaction hypothesis, elevation of NO production reduced, whereas inhibition of NO increased expression of endothelin-1 transcription levels in human endothelial cells [35] , and NO antagonized the endothelin receptor signaling by inhibiting calcium mobilization in CHO transfected cells [36] . Similarly, the production of endothelin from aortic vessels was inhibited in presence of NO and potentiated during NO inhibition [37] . In addition, antagonism of endothelin receptor A blunted the systemic and renal vasoconstrictor effects produced during NO inhibition in anesthetized rats [38] . In our model, it is possible that NO inhibition stimulated the endothelin system (by increasing transcriptional rates of bigendothelin mRNA, or by activating its intracellular signaling pathway). Alternatively, it is possible that the endothelin system was not activated, but its action became apparent because of the absence of the counterbalancing action of NO. Whatever the case is, the data obtained from ramipril + bosentan-treated animals suggest that endothelin has no major effect on RAS in presence of NO, whereas it mediates suppression of renin formation during inhibition of NO synthesis.
In conclusion, the mechanisms that activate the renin synthesis are not effective when endogenous NO synthesis is inhibited. The cause of this defect is probably due to increased entry of calcium into the renin-producing cells of afferent arterioles. This calcium influx is, at least partly, mediated by the action of endothelin presumably triggered by inhibition of NO synthesis. These data indicate the importance of the balance between endothelial vasodilators/vasoconstrictors in the physiological mechanisms controlling the renin-angiotensin system.
